Sangamo Therapeutics ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trader Talk

Sangamo Therapeutics (SGMO) Prices 11M Share Common Offering at $11.50/ShApril 4, 2019 8:03 AM Sangamo Therapeutics (SGMO) Hits Pre-Market High, Up 26%April 2, 2019 8:09 AM Sangamo Therapeutics (SGMO) Reports Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy DataApril 2, 2019 7:06 AM Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Phase 1/2 Interim Data For Investigational Hemophilia A Gene TherapyApril 2, 2019 7:01 AM Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy DataApril 2, 2019 7:00 AM Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer BioApril 2, 2019 7:00 AM Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene TherapyApril 2, 2019 7:00 AM Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene TherapyApril 2, 2019 7:00 AM Sangamo Therapeutics (SGMO) to Host April 2 Conference Call To Provide Clinical UpdateApril 1, 2019 5:23 PM